Primary Job Title Professor, Chair for Biotechnology of Neurodegenerative Diseases Primary Organization Tel Aviv University
Location Israel, Asia Regions Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA) Gender Female
LinkedIn View on LinkedIn
Dr. Solomon is Tel Aviv University Professor, Chair for Biotechnology of Neurodegenerative Diseases. She joined Tel-Aviv University in 1979 following post-doctoral studies and training at Harvard Medical School and Brigham and Women’s Hospital, Boston.
A world leader in Alzheimer’s research and pioneer of the immunotherapeutic approach, Dr.
Solomon has already attracted the pharma and biotech industry’s interest for three of her inventions in Alzheimer’s that have been licensed to Wyeth and Elan in a landmark deal with one product in Phase III clinical trials.
Her scientific interest is in the elucidation of the action of monoclonal antibodies (mAbs) on the structure and function of their corresponding antigens, in particular, the prevention of aggregation and solubilization of previously formed protein aggregates that play an important role in various human diseases, such as Down’s syndrome, Alzheimer’s disease, diabetes and/or cataracts, and in many other so-called amyloidosis disorders.
In 2002 the Alzheimer’s Association awarded Dr. Solomon the prestigious Zenith Award, the Alzheimer’s Drug Discovery Foundation supported her research in Alzheimer’s vaccines, and in 2007 Scientific American named her to the SciAm 50 list of leading innovative scientists for her work with phage to disaggregate Aβ plaque.
Dr. Solomon earned her PhD from the Weizmann Institute of Science, Rehovot, Israel in 1976 under the supervision of Dr. Ephraim Katchalski-Katzir, former President of the State of Israel.
